Minerva Neurosciences Inc (NERV) — Cash Flow-to-Debt Ratio
Minerva Neurosciences Inc (NERV) has a Cash Flow-to-Debt Ratio of -15.59x as of March 2026, meaning its operating cash flow of $-5.43 Billion could theoretically repay -16% of its total liabilities ($348.04 Million) in one year. See Minerva Neurosciences Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Minerva Neurosciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Minerva Neurosciences Inc across 14 annual periods. Also explore Minerva Neurosciences Inc (NERV) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Minerva Neurosciences Inc (2012–2025)
Year-by-year debt coverage analysis for Minerva Neurosciences Inc. For market capitalisation and broader financial context, see NERV stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -56.60x | $-13.51 Billion | $238.72 Million | ▼ -18091.0% |
| 2024 | -0.31x | $-19.55 Million | $62.84 Million | ▼ -79.6% |
| 2023 | -0.17x | $-14.78 Million | $85.36 Million | ▲ +47.2% |
| 2022 | -0.33x | $-24.65 Million | $75.11 Million | ▲ +7.8% |
| 2021 | -0.36x | $-24.60 Million | $69.15 Million | ▲ +94.8% |
| 2020 | -6.81x | $-33.82 Million | $4.96 Million | ▼ -680.0% |
| 2019 | -0.87x | $-43.43 Million | $49.72 Million | ▼ -1.8% |
| 2018 | -0.86x | $-41.94 Million | $48.87 Million | ▼ -1545.7% |
| 2017 | 0.06x | $3.09 Million | $52.10 Million | ▲ +106.2% |
| 2016 | -0.95x | $-25.69 Million | $26.96 Million | ▼ -7.0% |
| 2015 | -0.89x | $-24.27 Million | $27.26 Million | ▲ +58.0% |
| 2014 | -2.12x | $-35.96 Million | $16.95 Million | ▼ -783.4% |
| 2013 | -0.24x | $-2.16 Million | $9.00 Million | ▲ +95.0% |
| 2012 | -4.77x | $-908.54K | $190.29K | — |